Edinburgh, United Kingdom; 4th May 2023
Fitabeo Therapeutics, a clinical-stage speciality pharmaceutical company that develops and commercialises innovative medicines, has partnered with ILC Therapeutics, a UK-based biotech company that specialises in discovering and creating a new class of interferon drugs. Through this partnership, ILC Therapeutics will utilise Fitabeo Therapeutics’ advanced platform technologies for delivery of first-in-class hybrid interferons. This collaboration represents an exciting opportunity for both companies to combine their strengths and work towards advancing healthcare through cutting-edge pharmaceutical solutions.
This partnership represents a significant step forward in the companies’ shared mission to develop breakthrough treatments and improve health outcomes.
Mallikarjun Chityala, CEO of Fitabeo Therapeutics commented, “We are pleased to have partnered with ILC Therapeutics in advancing the development of new treatments. Their innovative technologies are ground-breaking, and our partnership will certainly enhance the potential for bringing medicines that will result in the advancement of healthcare.” ”
ILC Therapeutics CEO Dr Alan Walker said, “We are happy to be working with Fitabeo to adapt the delivery of hybrid interferons through oral thin films.”
For further information, please contact:
Mallikarjun Chityala, CEO, Fitabeo Therapeutics
[email protected]
Alan Walker, CEO, ILC Therapeutics
[email protected]
About Fitabeo Therapeutics
Fitabeo Therapeutics is a clinical-stage speciality pharmaceutical company that develops and commercialises innovative medicines focusing on indications where existing treatments are inadequate for the target population to provide better health outcomes. It deploys ground-breaking technologies to create medicines that enable decentralised patient care and provide equitable access to medicines across age groups and geographies.
About ILC Therapeutics
ILC Therapeutics is a UK-based biotechnology company and pioneer in the discovery and development of a ground-breaking new class of hybrid interferon drugs. Alfacyte, ILC Therapeutics’s lead hybrid interferon drug, is currently in development as an anti-viral medicine for the treatment of upper respiratory tract viral infections including SARS-CoV-2 which causes Covid-19.
